Itch is a protective sensation producing a desire to scratch. Pathologic itch can be a chronic symptom of illnesses such as uremia, cholestatic liver disease, neuropathies and dermatitis, however current therapeutic options are limited. Many types of cell surface receptors, including those present on cells in the skin, on sensory neurons and on neurons in the spinal cord, have been implicated in itch signaling. The role of G protein signaling in the regulation of pruriception is poorly understood. We identify here 2 G protein signaling components whose mutation impairs itch sensation. R7bp (a.k.a. Rgs7bp) is a palmitoylated membrane anchoring protein expressed in neurons that facilitates Gai/o -directed GTPase activating protein activity mediated by the Gb5/R7-RGS complex. Knockout of R7bp diminishes scratching responses to multiple cutaneously applied and intrathecally-administered pruritogens in mice. Knock-in to mice of a GTPase activating protein-insensitive mutant of Gao (Gnao1 G184S/1) produces a similar pruriceptive phenotype. The pruriceptive defect in R7bp knockout mice was rescued in double knockout mice also lacking Oprk1, encoding the G protein-coupled kappa-opioid receptor whose activation is known to inhibit itch sensation. In a model of atopic dermatitis (eczema), R7bp knockout mice showed diminished scratching behavior and enhanced sensitivity to kappa opioid agonists. Taken together, our results indicate that R7bp is a key regulator of itch sensation and suggest the potential targeting of R7bp-dependent GTPase activating protein activity as a novel therapeutic strategy for pathological itch.
Introduction
Itch is an irritating sensation that typically alerts us to the presence on our skin's surface of potentially harmful agents, such as fungi, parasites, insects, and certain alkaloids. The itch sensation triggers a desire to scratch. Like pain, itch is a protective sensation that promotes behavior to minimize damage to the host from harmful environmental factors. Itch detection begins in the skin, is conveyed by afferent sensory neurons that project to the dorsal horn of the spinal cord, and traverses at least 2 spinal interneurons before reaching spinal projection neurons that transmit the signal to higher brain centers resulting in conscious pruriception. 4, 6, 9, 12, 28 In contrast to acute itch, pathologic itch can be a chronic and often-debilitating manifestation of systemic and organ-specific illness. 46 Many types of receptors, present on cells in the skin, on sensory neurons and on neurons in the spinal cord, have been implicated in itch signaling. Such receptors include both G protein-coupled receptors (GPCR) and non-GPCR.
Regulator of G protein signaling (RGS) proteins negatively regulate GPCR signaling in many cell types. 31 RGS proteins act as GTPase activating proteins (GAPs) for G protein a subunits, accelerating the intrinsic hydrolysis rate of Ga-bound GTP to rapidly terminate G protein signaling. The R7-RGS subfamily of RGS proteins (RGS6, RGS7, RGS9, or RGS11) share similar domain architecture, including a G protein-g like (GGL) domain that enables heterodimerization with Gb5 (Fig. 1A) . 3, 33, 38 Gb5 and R7-RGS proteins can be found in a heterotrimeric complex with R7-binding protein (R7BP, a.k.a. RGS7BP), a palmitoylated membrane-anchoring protein (Fig. 1A ) (see Refs. 3,16 for reviews). The regulatory effects of the Gb5/R7-RGS complex on GPCR signaling and its Gai/o-directed GAP activity are greatly enhanced by R7BP palmitoylation and membrane anchoring. 7, 30 A body of in vitro evidence suggests that the GAP activity of Gb5/R7-RGS-containing complexes is specific for pertussis toxin-sensitive Ga subunits (Gao and/or Gai). 11, 30, 34, 35 The physiology of the endogenous Gb5/R7-RGS/R7BP complex within signaling circuits of the nervous system in vivo however is poorly understood.
We herein identify R7bp as a previously unsuspected critical regulator of acute and chronic pruriception in vivo, whose function to promote Gai/o-directed GAP activity may represent a novel target for the therapy of pathological itch. Nociceptive somatosensation is largely preserved in mice lacking R7bp. (A) Schematic illustration of R7bp, in complex with R7-RGS and Gb5 proteins, and heterotrimeric G protein Gai/o subunit, the target of Gb5/R7-RGS mediated GTPase activating protein (GAP) activity, positioned near the inner face of the plasma membrane. R7bp facilitates the GAP activity of the Gb5/R7-RGS complex through its membrane-anchoring function. Following Gi/o activation by agonist-activated Gi/ o-coupled G protein coupled receptor (GPCR), the GAP activity of the Gb5/R7-RGS complex (arrow) helps to terminate signaling through Gai/o and Gbg. R7bp is shown anchored to the plasma membrane by dual palmitoylation (2 squiggles), Gai/o by myristoylation (single squiggle), and Gbg by g-isoprenylation (single squiggle). The R7-RGS subfamily of RGS proteins (RGS6, RGS7, RGS9, and RGS11) shares a similar domain architecture: an N-terminal DEP/DHEX domain (the putative binding site of R7bp), followed by a G-gamma-like domain (GGL) that imparts the ability to bind Gb5, and a C-terminal RGS core domain that possesses GAP activity directed against Gai/o (arrow). (B) Sections through lumbar dorsal root ganglia (DRG) harvested from wild type (WT) (upper panel) and R7bp knockout (KO) (lower panel) mice and hybridized in situ with antisense probes against Gb5, R7bp, and the R7-RGS family members Rgs7 and Rgs9 showed no obvious differences in transcript expression. (C) Sections through DRG from WT and R7bp KO mice hybridized in situ with an antisense probe against the capsaicin-binding transient receptor potential cation channel subfamily V member 1 (Trpv1) showed no obvious differences in transcript expression. (D) No significant differences between WT and R7bp KO littermates were observed in the eye wipe assay using the Trpv1 agonist capsaicin (CAP). Results using phosphate-buffered saline (PBS) are shown for comparison. (E) No significant differences between WT and R7bp KO littermates were noted in the tail immersion test of thermal nociception. (F) R7bp KO mice exhibited an increased latency in 53˚C hot plate testing compared to WT littermates. (G) No obvious differences in mas-related receptor Mrgprd transcript expression in DRG from WT vs R7bp KO mice were observed by in situ hybridization. (H) No significant differences between WT and R7bp KO littermates were seen with Von Frey filament behavioral testing of mechanical nociception. (I) Results of the tail withdrawal assay using the Randall-Selitto test showed no significant difference between WT and R7bp KO littermates. (J) No significant differences between WT and R7bp KO littermates were observed in the eye wipe test of chemical nociception using the Trpa1 agonist mustard oil (MO). Results using phosphate-buffered saline (PBS) are shown for comparison. Statistics and representative figure reporting: For panels C and G, the hybridization experiment was repeated twice with similar results, using previously published probes. 32 For B, the hybridization experiment was repeated 3 times for each probe with similar results. In (D-F and H-J) the evaluator was blind to the genotype of the mouse being tested. In (D-F and H-J) the 2-tailed unpaired Student's t test was employed, with bars indicating mean 6 SEM. For panels D, H, and J, n 5 number of mice from each genotype tested (for panel D, PBS WT n 5 6; CAP WT n 5 9; PBS KO n 5 5; CAP KO n 5 8; for panel H, n 5 8; for panel J, PBS WT n 5 6; MO WT n 5 7; PBS KO n 5 6; MO KO n 5 7). For panels E, F, and I, n 5 number of mice tested (for panel E, WT n 5 7, KO n 5 8, with mice tested 2 or 3 times, with results from individual mice averaged; for panel F, WT n 5 14, KO n 5 10, with mice tested 3 times, with results from individual mice averaged; for panel I, WT n 5 8, KO n 5 7, with mice tested 3 times, with results from individual mice averaged.). P values: (D) for PBS, P 5 0.95, for CAP, P 5 0.91; (E) P 5 0.1; (F) ***P 5 0.0002; (H) P 5 0.63; (I) P 5 0.27; (J) for PBS, P 5 0.84, for MO, P 5 0.80. germline deletion of exons 1 and 2 of R7bp in a C57BL/6 background were a generous gift of Dr. Kirill A. Martemyanov, University of Minnesota (currently at the Department of Neuroscience, Scripps Florida). 2 Mice heterozygous for R7bp deletion were bred to generate wild type and R7bp homozygous KO pups for testing. Kappa-opioid receptor (Oprk1) knockout mice (B6.129S2-Oprk1 tm1Kff /J; Stock No. 007558) were obtained from The Jackson Laboratory (Bar Harbor, ME). The generation and characterization of mice harboring a heterozygous gain-of-function knock-in mutation in Gnao1 that prevents Gao turnoff by regulators of G protein signaling proteins (Gnao1 G184S/1) were previously described. 8, 18 For this study Gnao1 G184S/1 heterozygotes in a C57BL/6 background were employed. Mouse genotyping was performed by QPCR analysis of genomic DNA extracted from mouse tails using the DirectPCR (tail) solution (Cat. No. 102-T; Viagen, Los Angeles, CA) according to manufacturer's instructions. The R7bp knock out allele was identified employing the primer pair, Fwd: 59-CTG CAA GCC AGT AGT GCC AGT CCC-39, and Rev: 59-GGA ACT TCG CTA GAC TAG TAC GCG T-39. The wild type R7bp allele was identified employing the primer pair, Fwd: 59-TCC AAG AGT TCA ACA CGC AAG TGG-39, and Rev: 59-GGC CAT TTC ACA GCC TTT GGT TCT-39. The Oprk1 knock out allele was identified employing the primer pair, Fwd: 59-AGG GGA TTT CAA CCT GTC TG-39, and Rev: 59-CTC CAG ACT GCC TTG GGA AAA-39. The wild type Oprk1 allele was identified employing the primer pair, Fwd: 59-AGG GGA TTT CAA CCT GTC TG-39, and Rev: 59-CCA CAC TGC CAT TAC TGT CG-39.
Behavioral testing
For all behavioral testing the evaluator was blind to the genotype of the mouse being tested. Age-matched female mice from littermate cohorts, 3 to 8 months of age, were used for all the experiments. All behavioral testing was performed during the light cycle (daylight hours). Animal experiments were conducted according to NIH guidelines using protocols approved by the Animal Care and Use Committee of the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases.
Motor coordination testing
Motor coordination testing on the accelerating rotarod and open field-testing for locomotor activity were performed as previously described. 47 
Testing for nociception
The hot plate test for thermal analgesia was performed as described by Terzi et al. 41 Thermal nociception using the tail immersion assay was assayed as previously described by Sun et al. 40 The von Frey test for mechanical pain was performed as described by Sun and Chen 39 using a set of calibrated von Frey filaments. Each filament was applied 5 consecutive times and the smallest filament that evoked reflexive flinches of the paw on 3 of the 5 trials was taken as the paw withdrawal threshold. Mechanical nociception was estimated by the Randall-Selitto assay utilizing an electronic algesimeter (IITC 2500 Digital Paw Pressure Meter; IITC Life Science, Woodland Hills, CA) as previously described. 37 The nocifensive response to the activation of specific nociceptors in the trigeminal sensory ganglia that innervates the cornea was assessed by the eye wipe assay, using drops (50 mL) of dilute capsaicin (100 mM, Sigma No. M2028, Sigma-Aldrich, St. Louis, MO) or mustard oil-allyl isothiocyanate (10 mM, Sigma No.
W203408, Sigma-Aldrich) dissolved in PBS, as previously described. 17 
Behavioral responses to intradermal pruritogens
The scratch response to intradermal injection of pruritogens was assayed as previously described by Sun et al. 40 Briefly, after 2 hours of cage acclimation mice were injected intradermally with a pruritogen dissolved freshly in sterile PBS (10 mL) in the nape of the neck and then returned to their cage. Hind limb scratching behavior directed towards the injection site was recorded for 30 minutes at 5-minute intervals. A scratch was defined as the lifting of the hind limb towards the injection sites and then replacing it back on the floor. This is regardless of the number of scratching strokes taking place between the 2 movements. 40 The pruritogens employed were of the highest purity commercially available and included classical pruritogens (endothelin-1 [25 , and the cytokine thymic stromal lymphopoietin (2.5 mg/10 mL) (Cat. No. 148498; eBioscience, San Diego, CA). Individual mice were used for the testing of no more than 3 cutaneous or intrathecal pruritogens in the behavioral study, with at least 15 days of rest/washout in their home cage between tests.
Behavioral responses to intrathecal pruritogens
The scratch response to the intrathecal drug injection of pruritogens was performed as described by Hylden and Wilcox 13 using a sterile, disposable 30 gauge, ½ inch needle and a total injection volume of 10 mL. 32 Penetration of the lumbar spinal dura mater by the needle was confirmed by the classic tail flick response.
14 Scratching responses were monitored over a period of 45 minutes following injection. Peptides for intrathecal testing were of the highest purity commercially available, and included gastrin-releasing peptide (GRP) (1-5 nmol) (Bachem, Cat. No. H3120, Bachem, Torrance, CA) and B-type natriuretic peptide (BNP; Nppb) (1-5 nmol) (Sigma, Cat. No. B9901, SigmaAldrich). 32 Individual mice were used for the testing of no more than 3 cutaneous or intrathecal pruritogens in the behavioral study, with at least 15 days of rest/washout in their home cage between tests.
Atopic dermatitis (eczema) model
A mouse model of atopic dermatitis was employed as described previously with minor modification. 23, 40 Mice were shaved on the nape of the neck and sensitized by painting 0.2 mL of diphenylcyclopropenone (DCP) (1% wt/vol, dissolved in acetone) once on the shaved skin. Seven days after sensitization mice were again challenged by painting 0.2 mL of DCP (0.5%) on the same location daily, for 10 consecutive days. Thirty minutes following DCP application, mice were injected with saline intraperitoneally and then beginning 30 minutes post injection scratching behavior directed toward the painted skin area was quantified for the following 30 minutes. Scratching behavior was determined on days 1 to 5 and on days 8 to 10 during the 10 consecutive days of daily topical DCP application. On the fifth, eighth and 10th days, just after quantifying scratching behavior for 30 minutes (after the intraperitoneal saline injection), mice were given an intraperitoneal injection of the specific kappa opioid receptor agonist U50,488 at 0.1, 0.25 and 2.5 mg/kg respectively. Thirty minutes after agonist administration mice scratching behavior directed towards the DCP painted area was counted again for another 30 minutes. The relative scratching response was calculated as the ratio of bouts of scratching following U50,488 injection to that following the preceding saline injection approximately an hour earlier in the same mouse.
Preparation of probes for in situ hybridization
Digoxigenin-labeled RNA probes were made by in vitro transcription using DIG RNA labeling Kit (SP6/T7) (Cat. No. 11175025910; Roche Life Science, Indianapolis, IN). For RNA probe generation from the SP6/T7 dual promoter vector, DNA templates in the range of 500 to 700 bp derived from cDNA were used. After preparation, probes were analyzed for RNA integrity and stored in aliquots at 270˚C. PCR primers used to generate murine cDNA-derived DNA template inserts for the SP6/T7 dual promoter vector were: R7bp, Fwd: 59-CTG TAC CGA GAG TTG GTC ATT T-39, Rev: 59-GAA CCT TCT CTT CCG TCT TCT G-39; Rgs7, Fwd: 59-CAT GGC TAC TTC TTT CCC ATC T-39, Rev: 59-CCC TCT GTT GAC TTG GTT CTT-39; Gnb5, Fwd: 59-ATC TGC CCT CAG GTC ATA GA-39, Rev: 59-GCT TGT GGT GGT CTG GSA TAA TA-39; Rgs9, Fwd: 59-GAC ACA GAC TAC GCC ATC TAT C-39, Rev: 59-CAT CTC TCC ACT CGC ATC TT-39; Oprk1, Fwd: 59-AAG TCA GGG AAG ATG TGG ATG T-39, Rev: 59-ACT GCA ACT ACT ACC AGC ACC A-39. Primers used to generate other ISH probes were as previously described. 32 
In situ hybridization
Mice were anesthetized with avertin and their spinal cord and dorsal root ganglia were rapidly dissected out. Tissues were frozen with OCT embedding medium (Electron Microscopy Sciences [EMS], Hatfield, PA) and 12 micron-thick sections were cut on a cryostat at 220˚C. Pairs of wild type and R7bp knockout sections, from either lumbar spinal cord or pooled dorsal root ganglia, were carefully collected onto the same slides and allowed to dry for 10 minutes at room temperature. Sections were fixed in 4% (wt/vol) paraformaldehyde (EMS) dissolved in RNasefree PBS for 10 minutes. Sections were washed in RNase-free PBS 3 times and then permeabilized in 10% TritonX-100 (Sigma Cat. No. T8787, Sigma-Aldrich) (vol/vol) for 5 minutes. After permeabilization, sections were acetylated in acetylation buffer for 10 minutes at room temperature. (Acetylation buffer was prepared by combining 675 mL triethanolamine [Cat. No. 90279; Sigma-Aldrich] with 125 mL of acetic anhydride [Cat. No. 320102; Sigma-Aldrich] in 50 mL of DEPC-treated water; acetylation buffer was prepared fresh and used within 10 minutes of preparation.) After acetylation, sections were washed in PBS 3 times. Sections were then incubated with digoxigenin-labeled RNA probes overnight at 68˚C. Sections were then washed in 30.2 SSC buffer at 70˚C for 30 minutes. Sections were twice washed in a buffer containing 0.1 M maleic acid (Cat. No. M0375; Sigma-Aldrich) in 0.15 M NaCl, brought to pH 7.5 with solid NaOH, and then blocked with 1% (wt/vol) BSA for 30 minutes. Next, sections were incubated with alkaline phosphatase-labeled anti-digoxigenin antibodies (Roche) for 6 to 7 hours at room temperature. After incubation the sections were washed extensively and nitro blue tetrazolium/5-bromo-4-chloro-3-indolylphosphate (NBT/BCIP) (Roche) developing agent was added. Sections were observed at different time intervals during color development. Pictures were taken using an inverted Leica microscope.
For double fluorescent in situ hybridization (FISH), digoxigeninlabeled RNA probes were made for R7bp and fluorescein-labeled RNA probes were made for Oprk1 by in vitro transcription as described above. Horseradish peroxidase-conjugated antidigoxigenin antibody (Cat. No. 11207733910; Roche) and alkaline phosphatase-conjugated anti-fluorescein antibody (Cat. No. 11426346910; Roche) were used for detecting the RNA probes. The HNPP Fluorescent Detection Set (Cat. No. 11758888001; Roche) was used for detecting alkaline phosphatase-conjugated antibody and TSA Plus Fluorescence Kit (Cat. No. NEL741001KT; Perkin Elmer, Waltham, MA) was used for detecting horseradish peroxidase-conjugated antibody. Sections were washed at the end of reaction in PBS 5 to 6 times and mounted with mounting medium containing DAPI. Sections were immediately analyzed using a Leica inverted fluorescent microscope with capture of digital images.
Quantification of dorsal root ganglion cells expressing pruriceptive markers
Microscopic sections of dorsal root ganglion (DRG) cells expressing MrgprA3 or Nppb by in situ hybridization (ISH) were analyzed using the count tool of the Adobe Photoshop CC 2015 software. Images of ISH-stained sections were opened in TIFF format and each stained cell of every DRG section was counted by manually with computer mouse clicks. Six different DRG sections were counted for each genotype (wild type and R7BP knockout mice), with the evaluator blind to the genotype of the mouse from which the section originated.
Induction and quantification of spinal neuron c-Fos expression in response to injected pruritogen
Hundred microgram of compound 48/80 or 200 mg of chloroquine dissolved in PBS in a volume of 50 mL were injected subcutaneously into the nape of the neck by an investigator blind to genotype of the mouse under study. Four to 5 pairs of wild-type and R7bp knockout mouse littermates were analyzed per pruritogen. As a control, 50 mL of PBS vehicle only was injected in wild-type mice to estimate the effect of the skin prick sensation as a background signal. Two hours after injection, mice were anesthetized using Avertin and perfused with 20 mL of cold PBS followed by 25 mL of cold 4% paraformaldehyde dissolved in PBS. Whole spinal cords were dissected and tissues were post-fixed for 1 hour at 4˚C, washed extensively with PBS, cryopreserved in 20% sucrose in PBS overnight, embedded in OTC (Electron Microscopy Sciences, Hatfield, PA), and frozen. Serial sections of 20 mm thickness were cut from cervical spinal cord on a cryostat and placed on slides. Tissue sections from wild-type and R7bp knockout mice were processed on the same slide to minimize differences in handling. For immunostaining, sections were blocked in 10% BSA and 0.25% Triton X-100 in PBS for 1 hour at RT. Sections were incubated with primary antibodies (c-Fos, sc-52; Santa Cruz, Dallas, TX; Anti-NeuN Antibody, clone A60, MAB377; EMD Millipore, Billerica, MA) in blocking solution overnight at 4˚C. Slides were washed 4 times 5 minutes in PBS containing 0.1% Triton X-100. Detection was carried out using Alexa-Fluor-labeled secondary antibodies diluted 1: 500 in blocking solution. Sections were mounted using glycerol containing the nuclear dye DAPI for 1 minute at room temperature. Sections were visualized using a BZ-9000 fluorescence microscope (Keyence) at 310 magnification and digital images were captured for counting. Four to 11 sections per animal were used for quantification, sampled across ;1200 to 1500 mm axial distance 
Culture of dorsal root ganglion cells and intracellular calcium mobilization assay
Preparation and dissociation of mouse dorsal root ganglion cells was performed following the procedure of Malin et al., 29 with minor modification as noted. Wild-type and R7bp knockout cagematched littermate mice were anesthetized using avertin and the dorsal root ganglia were rapidly dissected (without prior animal perfusion). The sensory ganglia were washed once in cold Hanks' Balanced Salt solution without calcium or magnesium (GIBCO, Gaithersburg, MD) and incubated with papain (Cat. No. NM100200; NeuroPapain, Genlantis, San Diego, CA) for 10 minutes at 37˚followed by collagenase, type 2 (Cat. No. LS004174; Worthington Biochemical Corp, Lakewood, NJ) and dispase II (Cat. No. 17-105-041, GIBCO) at 37˚. The ganglia were suspended in culture Ham's F12 medium containing 10% fetal calf serum, penicillin and streptomycin and triturated with fire polished Pasteur pipettes to isolate single neurons. The neurons with medium were plated onto Poly-D-lysine/laminin coated cover slips (Cat. No. 354087; Corning, Inc., Corning, NY) and grown in culture at 37˚with 5% CO 2 .
A fluorescence-based assay for detecting intracellular calcium mobilization in the cultured dorsal root ganglia cells employed the Rhod-4 No Wash Calcium Assay Kit (Cat. No. ab112157; Abcam, Cambridge, MA), following the manufacturer's instructions for intracellular calcium assay. In short, culture medium was removed and Rhod-4 dye containing buffer was gently added to cells, followed by incubation at 37˚for 30 minutes followed by 20 minutes at room temperature. For imaging and quantification of ligand-induced intracellular calcium mobilization, confocal images were acquired using a Leica DMI 6000 confocal microscope (Leica Microsystems, Exton, PA) enabled with 320 multiimmersion objective NA 1.25. Images were acquired using high sensitive hybrid detectors to achieve a maximum signal to noise ratio and the time lapse images of the confocal scan were acquired every second over a 3 minute period. Sensory neuronal cultures were treated with either chloroquine or histamine (50 mM, final concentration), added after the first 10 seconds to establish a baseline and observe the steady-state changes in calcium mobilization in response to the ligand treatment. Acquired confocal images were post-processed using Imaris image processing software (Bitplane USA, Concord, MA). Fluorescent intensity changes were quantified using fixed parameters across the entire set of captured images.
Statistical methods
No sample size calculation was used to predetermine sample sizes. Sample size was chosen as a balance between establishing confidence in reproducibility (on one hand) and practical considerations, such as the time required to breed animals of a particular age, gender, and genotype (on the other). Sample size is reported in the legend to each figure. Data distribution was assumed to be normal, but this was not formally tested. For comparison of 2 data sets, the 2-tailed unpaired Student's t test or 2-way ANOVA test was employed, as appropriate. No data points were excluded. Significance level was set at P , 0.05 and all data are reported as mean 6 SEM. Prism computer software, Version 5.0f (GraphPad Software, Inc, La Jolla, CA) was employed for the statistical analysis.
Results

Nociceptive somatosensation is largely preserved in mice lacking R7bp
R7bp is thought to function as a component of a heterotrimeric complex with Gb5 and R7-RGS proteins (Fig. 1A) , and R7bp and Rgs7 proteins are expressed in mouse dorsal root ganglia (DRG). 24 The expression of R7bp and its potential functional partners in the heterotrimeric Gb5/R7-RGS/R7BP complex was verified by in situ hybridization (ISH) in wild-type and R7bp KO mice. R7bp, Gb5, Rgs7, and Rgs9 transcripts were readily identified in wild-type DRG (Fig. 1B upper panel) , and knockout of R7bp did not appear to significantly affect the expression of the latter transcripts (Fig. 1B lower panel) . We therefore wondered if the R7bp present in sensory neurons might regulate one or more modality of somatosensation.
Vertebrates utilize the capsaicin-sensitive Trpv1 channel expressed in peripheral sensory neurons for thermal nociception. DRG harvested from wild-type and R7bp KO mice showed no apparent difference in the expression of Trpv1 (Fig. 1C) . Acute thermal nociception, as determined by the eye wipe test with the Trpv1 agonist capsaicin and the acute tail immersion assay, respectively, were unchanged in R7bp KO mice (Fig. 1D, E) . Thermal nociception using the hot plate test was diminished in the R7bp KO mice as evidenced by enhanced basal latency of paw withdrawal (Fig. 1F) , as previously reported. 48 In adult mice, sensory neurons expressing the G proteincoupled receptor Mrgprd are required for the behavioral response to noxious mechanical stimuli. 5 There was no obvious difference in the expression of Mrgprd in DRG from R7bp KO mice vs control (Fig. 1G) . Furthermore mechanical nociception was preserved in R7bp KO mice (Fig. 1H, I ).
Acute chemical nociception in response to mustard oil (acting through Trpa1 receptors) also appeared unchanged in R7bp KO mice (Fig. 1J) . Since nociception was largely preserved in R7bp KO mice we investigated if the sense of itch was altered.
R7bp-knockout mice exhibit impaired pruriception
The scratching response to the intradermal application of a variety of classical histamine-dependent and histamine-independent pruritogens acting directly and indirectly through GPCRs was markedly deficient in R7bp KO mice compared to that of their wildtype littermates ( Fig. 2A-E) . To exclude motor difficulties that might impact their ability to scratch, we confirmed that mice lacking R7bp exhibited normal motor coordination and locomotor activity, consistent with previous reports (data not shown). 1 We proceeded to study a more diverse set of cutaneous pruritogens in order to better demarcate the pruriceptive defect in these mutant mice.
In wild-type mice we confirmed that the toll-like receptor TLR3 agonist polyinosinic:polycytidylic acid (poly [I:C]), a structural analog of double-stranded (ds) RNA such as that found in dsRNA viruses, but not the TLR3-inactive synthetic double-stranded DNA analog N) the evaluator was blind to the genotype of the mouse from which the DRG section originated. In (A-K and M, N) the 2-tailed unpaired Student's t test was employed, with bars indicating mean 6 SEM. The hybridization experiment in panel (L) was repeated twice with similar results, using previously published probes. 32 For O and P, 2-way ANOVA was employed with data points indicating mean 6 SEM. For panels A-K, n 5 number of mice from each genotype tested (for panel A, WT n 5 10, KO n 5 9; for panel B, WT n 5 8, KO n 5 9; for panel C, WT n 5 10, KO n 5 11; for panel D, WT n 5 8, KO n 5 10; for panel E, n 5 8; for panel F, n 5 8 for each compound; for panel G, n 5 8; for panel H, n 5 7; for panel I, n 5 9; for panel J, WT n 5 8, KO n 5 6; for panel K, n 5 8). For M and N, n 5 the number of sections per genotype counted (n 5 6). For O and P, n 5 4 calcium mobilization experiments per genotype per drug. P values: (A) ***P 5 0.0001; (B) ***P 5 0.0004; (C) ****P , 0.0001; (D) ***P 5 0.0004; (E) **P 5 0.004; (F) ***P 5 0.0005; (G) ***P 5 0.0002; (H) *P 5 0.04; (I) **P 5 0.002; (J) *P 5 0.04; (K) *P 5 0.014; (M) P 5 0.23; (N) P 5 0.06; (O) P 5 0.73; (P) P 5 0. 24. polydeoxyinosinic:polydeoxycytidylic acid (dI:dC), was a weak pruritogen (Fig. 2F) as was previously reported. 27 Mice lacking R7bp failed to respond to the pruritogenic effects of poly (I:C) (Fig. 2G) .
The R7bp KO mice also failed to respond to the cytokine thymic stromal lymphopoietin (TSLP), implicated in the pathogenesis of atopic dermatitis in humans 15 and shown to evoke scratching behavior in mice 44 ( Fig. 2H) , endothelin-1, a paracrine factor released from endothelial cells (Fig. 2I) , and the bile salts deoxycholate (DCA) and taurolithocholate (TLCA) implicated in the pruritus characteristic of cholestatic liver disease 20 ( Fig. 2J, K) . One explanation for the above findings could be a loss of pruriceptive sensory neurons in mice lacking R7bp. Using DRG sections labeled by ISH, we found that specific pruriceptive sensory neuronal markers, such as natriuretic peptide B (Nppb) 32 and mas-related GPCR MrgprA3, 25 appeared to be expressed normally in DRG from R7bp KO mice (Fig. 2L) . Cell counting experiments showed that knockout of R7bp caused no reduction in the number of DRG cells expressing either pruriceptive marker (Fig. 2M, N) . If anything in fact, the R7bp KO mice tended to have more DRG cells expressing the pruriceptive markers than controls, a difference that did not however achieve statistical significance.
Another explanation for the loss of scratching behavior observed in the R7bp KO mice could be a loss of sensitivity to pruritogens in primary pruriceptive neurons. To test this hypothesis, DRG were harvested from WT and R7bp KO mice, and primary sensory neurons were isolated by gentle protease treatment and cultured in vitro for testing, using ligand-induced mobilization of intracellular calcium as a functional assay. Treatment of the isolated sensory neurons with the prototypical pruritogens histamine and chloroquine triggered intracellular calcium release in a subset of sensory cells from both WT and R7bp KO mice over the 3 minute study period (Fig. 2O, P) , with no significant difference between genotypes detected (P 5 0.73, histamine; P 5 0.24, chloroquine, by 2-way ANOVA).
Given that loss of R7bp diminished the scratching behavior in response to multiple pruritogens acting through disparate classes of receptors, including non-GPCRs (Table 1) , we questioned our underlying hypothesis linking loss of R7bp's canonical function, namely facilitation of Gai/o-directed GAP activity, to the pruriceptive defects. We therefore sought independent confirmation of a linkage between loss of Gai/o-directed GAP activity and loss of pruriception.
3.3. Mice heterozygous for an RGS protein-insensitive mutant of Gao exhibit a pruriceptive defect similar to that of R7bp knockout mice Within R7bp-and Gb5/R7-RGS complex-expressing neurons, the amplitude of the intracellular signal transduced from agonist-activated Gi/o-coupled GPCRs represents a balance between receptor-driven Gi/o activation and Gi/o de-activation (Fig. 3A) . Signaling in neurons from mice lacking R7bp (Fig. 3B) or harboring an RGS protein-insensitive mutant form of Gai or Gao (Fig. 3C ) might be similarly enhanced.
Given the similarity of the predicted signaling phenotypes, we hypothesized that the pruriceptive phenotype of mice expressing a Gai/o subunit insensitive to the GAP activity of RGS proteins might be similar to that of R7bp KO mice if, in fact, the R7bp KO phenotype was due to loss of its canonical role in facilitating the Gai/o-directed GAP activity of Gb5/R7-RGS complexes.
We therefore tested pruriception in mice heterozygous for the G184S mutant of Gao (Gnao1 G184S/1). 8 This approach afforded the opportunity to test the hypothesis without any knowledge regarding the upstream Gi/o-coupled GPCR(s) that might be involved in R7bp-dependent pruriception. Because of the single amino acid mutation, the G184S mutant form of Gao fails to bind RGS proteins with high affinity and is insensitive to RGS protein GAP activity. 22 Mice homozygous for this mutation are not viable.
8 Table 1 Pruritogens With scratching responsiveness sensitive to R7bp knockout in mice. We found the scratching response to the intradermal application of both compound 48/80 and chloroquine was markedly deficient in Gnao1 G184S heterozygous mice (Fig.  3D, E respectively) . The similarity of the pruriceptive phenotype of Gnao1 G184S/1 mice to that of R7bp KO mice strongly suggested that it was loss of R7bp's canonical role as facilitator of Gai/o-directed GAP activity that was critical to the phenotype of the latter mice.
To help explain why the scratching response to such a diverse array of cutaneously applied pruritogens was affected in R7bp KO mice (Table 1) , and to account for the apparent lack of effect of R7bp KO on the number or sensitivity of primary pruriceptors ( Fig. 2L-P) , we decided to consider possible effects of R7bp loss in the central nervous system. To evaluate this possibility, we quantified behavioral responses to intrathecally-administered pruritogens.
Mice lacking R7bp show reduced scratching behavior in response to intrathecally-administered pruritogens
The itch sensation is conveyed by primary sensory neurons that release Nppb onto secondary pruriceptors in the spinal dorsal horn (Fig. 4A) . 32 Accordingly the intrathecal administration of Nppb induces scratching behavior in mice. 32 Secondary pruriceptors release gastrin-releasing peptide (GRP) onto tertiary pruriceptors in the superficial dorsal horn that express gastrin-releasing peptide receptors (Grpr) (Fig. 4A) .
32,39,40
Scratching behavior resulting from the intrathecal administration of Nppb is blocked by pretreatment with a Grpr antagonist. 19 Wild-type and Nppb 2/2 mice, but not Grpr 2/2 mice, exhibit scratching behavior in response to the intrathecal administration of GRP. 32, 39 We studied the scratching behavior in response to intrathecal Nppb and GRP in R7bp KO mice. The intrathecal administration of either Nppb (Fig. 4B) or GRP (Fig. 4C ) stimulated scratching behavior that was greatly diminished in mice lacking R7bp (Fig. 4B, C) ( Table 1) . We observed that, as in R7bp KO mice, Gnao1 G184S/1 mice also exhibited reduced scratching behavior in response to intrathecal GRP (Fig. 4D) .
The diminished responsiveness to intrathecal pruritogens observed suggested that the pruriceptive defect in R7bp KO mice involves R7bp actions at the spinal level. If this model were true, R7bp KO mice should also exhibit reduced activation of spinal neurons in response to cutaneously applied pruritogens. We tested this using an immunohistochemical assay for the activation of spinal neurons.
Mice lacking R7bp show impaired activation of spinal cord dorsal horn neurons in response to cutaneous pruritogens
We first confirmed the expression of R7bp and other components of the heterotrimeric Gb5/R7-RGS/R7BP complex in the spinal cord by ISH (Fig. 5A) . Transcript for R7bp was expressed widely in cells throughout the dorsal horn and intermediate zone of grey matter in wild-type mice (Fig. 5A upper panel, left) . Knockout of R7bp did not affect the level or pattern of Statistics reporting: In D and E, the evaluator was blind to the genotype of the mouse being tested. In D and E, the 2-tailed unpaired Student's t test was employed, with bars indicating mean 6 SEM. For panels D and E, n 5 number of mice from each genotype tested (n 5 8). P values: (D) ***P 5 0.0001; (E) ****P , 0.0001. expression of transcripts for Gb5, Rgs7, and Rgs9 (Fig. 5A,  lower panel) .
Cutaneous pruritogens can activate neurons in the superficial dorsal horn as evidenced by induction of the immediate early gene c-Fos in neuronal nuclei. 10, 45 We therefore reasoned that if the pruriceptive defect in R7bp KO mice resulted from diminished inter-neuronal signaling at the spinal level, there might be a corresponding reduction in the pruritogen-induced activation of c-Fos expression in neurons present in the superficial dorsal spinal cord. Intradermal administration of compound 48/80 induced c-Fos immunoreactivity in lateral spinal dorsal horn neurons of wild-type mice ( Fig. 5B upper panel; 5C) . Significantly fewer neurons demonstrated c-Fos induction in 48/80-treated R7bp KO mice or in PBS-treated wild-type mice ( Fig. 5B lower  panel; Fig. 5C ). Spinal lateral dorsal horn neuronal c-Fos induction in response to intradermal chloroquine administration was also reduced in R7bp KO mice (Fig. 5D) .
Taken together, the results above were most consistent with a model in which the impaired scratching behavior in response to the cutaneous application of pruritogens in R7bp KO mice resulted (1) primarily from disruption of the itch sensory circuitry at the spinal level, and (2) from the loss of the canonical function of R7bp to facilitate GAP activity directed against Gai/o. We therefore considered candidate Gi/o-coupled GPCR-regulated pathways in the spinal cord that were normally inhibitory to pruriception. Loss of R7bp-facilitated GAP activity in such a pathway could lead to an exaggeration of the normal anti-pruriceptive inhibitory signal, resulting in a loss-of-pruriception phenotype.
Knockout of the kappa-opioid receptor rescues the pruriceptive defects of R7bp knockout mice
Recently, a population of inhibitory interneurons in the dorsal horn was identified that express the transcription factor Bhlhb5 and are abolished by knockout of Bhlhb5 during development. 36 These spinal interneurons, termed B5-I neurons, are involved in the tonic inhibition of itch.
17,36 B5-I neurons, thought to be GABAergic or glycinergic, also utilize dynorphin as an inhibitory neuromodulator. 17, 36 Dynorphin is the endogenous ligand for the kappa-opioid receptor, a Gi/o-coupled GPCR encoded by Oprk1. Loss of R7bp from neurons expressing kappa-opioid receptors and positioned downstream from B5-I neurons in the pruriceptive signaling pathway could lead to an exaggeration of normal inhibitory neuromodulation and a loss-of-pruriception phenotype. We therefore hypothesized that, if this were the case, knockout of the kappa-opioid receptor might reverse the loss-ofpruriception phenotype in R7bp KO mice.
To explore this possibility, pruriception was tested in mice singly deficient for Oprk1 or for R7bp, in Oprk1/R7bp double KO mice, and in their wild-type littermates. As previously shown, the scratching response to the intradermal application of both compound 48/80 and chloroquine was deficient in R7bp KO mice compared to their wild-type littermates (Fig. 6A, B) . While the knockout of Oprk1 alone had no effect, the double knockout of Oprk1 and R7bp completely reversed the deficiency of scratching behavior in response to intradermal 48/80 and chloroquine observed in mice deficient for R7bp alone (Fig. 6A, B) .
In response to intrathecal GRP, R7bp KO mice exhibited diminished scratching behavior, as previously shown (Fig. 6C) . Mice deficient for Oprk1 also showed a diminished response to intrathecal GRP, however mice doubly knocked out for Oprk1 and R7bp showed a normal scratching response to intrathecal GRP, indicating mutual rescue of the diminished scratching responses seen with either single gene deficiency (Fig. 6C) . That single knockout of Oprk1 resulted in diminished scratching in response to intrathecal GRP was an incidental and unexpected finding, not readily explained by current models. Mice lacking R7bp (R7bp KO) (filled triangles) or their wild-type littermates (WT) (filled circles) were evaluated for scratching behavior during a ten-day period of daily topical application of diphenylcyclopropenone (DCP) in a model of atopic dermatitis, over a period of 30 minutes on days 1 to 5 and 8 to 10, as described in Methods. (E) The relative scratching behavior of wild-type (open bars) and R7bp KO mouse littermates (filled bars) was calculated as the ratio of scratching behavior following injection of the specific kappa opioid receptor agonist U50,488 injection to that following a preceding saline injection in the same mouse on day 5, day 8, and day 10 of topical DCP treatment in a model of atopic dermatitis (see panel D) as described in Methods. Mice were given an intraperitoneal injection of U50,488 at a dose of 0.1, 0.25 and 2.5 mg/kg on day 5, day 8, and day 10 respectively. Statistics reporting: For panels A-E, the evaluator was blind to the genotype of the mouse being tested. In A-C and E, the 2-tailed unpaired Student's t test was employed, with bars indicating mean 6 SEM. In D, 2-way ANOVA was employed with bars indicating mean 6 SEM. For panels A-E, n 5 number of mice from each genotype tested (A-C, WT n 5 6, R7BP KO n 5 7, DKO n 5 6; D and E, WT n 5 10, R7BP KO n 5 8). We showed above that R7bp KO mice exhibit diminished scratching in response to cutaneous application of the cytokine TSLP (Fig. 2I) . Since TSLP signaling has been implicated in the pathogenesis of atopic dermatitis, 15 we studied the scratching behavior R7bp KO mice and their wild-type littermates in a mouse model of atopic dermatitis induced by the chronic topical application of diphenylcyclopropenone (DCP). 23 Following the sensitization period, mice lacking R7bp exhibited significantly diminished scratching behavior over the 10 days of the trial compared to control (P , 0.0001, 2-way ANOVA) (Fig. 6D) .
Since we previously showed the effects of R7bp KO on acute pruritogen-induced scratching behavior depended on the presence of kappa opioid receptors, we tested the effect of U50,488, a specific kappa receptor agonist, on chronic itch during the latter portion of DCP trial. Since during this time the control and R7bp KO mice had different levels of scratching behavior, we compared the relative scratching behavior following U50,488 injection to that following a preceding saline injection an hour earlier in the same mouse. Control mice exhibited no difference in relative scratching behavior in response to the 0.1 and 0.25 mg/kg doses of U50,488, whereas R7bp KO mice showed a significant reduction (Fig. 6E) . A heightened sensitivity to U50,488 treatment in the R7bp KO mice was particularly evident with the 0.25 mg/kg dose following which the mutant mice showed a nearly 90% Primary pruriceptors activated by cutaneous pruritogens activate Npra1 secondary pruriceptors (blue) that in turn activate Grpr1 tertiary pruriceptors (yellow). The itch signal then traverses a yet-to-be-defined spinal circuit before it ascends via the contralateral spino-thalamic tract to higher brain centers resulting in conscious pruriception. Our model hypothesizes the presence of Oprk11 neurons containing R7bp (red) that facilitates Gb5/R7-RGS complex-mediated GTPase activating protein (GAP) activity targeting Gi/o coupled to the kappa opioid receptor (KOR). The KOR in this model is activated by its endogenous ligand, dynorphin, released from a yet-to-be-identified spinal neuron located upstream that is tonically inhibitory to the pruriceptive pathway. A candidate for this dynorphinergic neuron in this model is the Bhlhb51 inhibitory spinal interneuron (B5-I) previously identified by Ross et al. 17, 36 Activation of the KOR inhibits itch, and knockout of R7bp in these cells promotes forward signalling through the KOR that exaggerates (1) the basal tonic dynorphinergic inhibition of itch resulting in a loss-of-pruriception phenotype, and (2) the antipruritic effects of exogenous kappa opioid agonists. Since R7bp knockout results in loss-of-pruriception to intrathecally-administered gastrin-releasing peptide (GRP), R7bp-regulated inhibition of itch sensation must act at the level of, or central to, the Grpr1 tertiary pruriceptors (yellow).
